DSS-Induced Colitis: Mechanisms, Immune Response, and Health Impacts

Dextran sodium sulfate, usually called DSS, is a water-soluble sulfated polysaccharide that, when added to the drinking water of laboratory mice, reliably produces intestinal inflammation resembling human ulcerative colitis. The model is one of the most widely used in gut immunology because it is simple to set up and reproduces many of the clinical and molecular features seen in patients with inflammatory bowel disease.¹ What makes DSS colitis so informative is that it unfolds in distinct, well-characterized steps: barrier damage, microbial invasion, immune activation, tissue destruction, and systemic fallout. Understanding each of those steps reveals why gut inflammation is far more than a local problem.

How DSS Breaks the Gut Barrier

The first event is not an immune attack. DSS damages the mucus layer that lines the colon before any immune cells get involved. The colon’s inner mucus layer is normally dense enough to keep bacteria from touching the epithelial cells beneath it. When colon tissue is exposed to DSS in the lab, that inner mucus thins and becomes permeable to bacteria-sized particles within about fifteen minutes. Bacteria reach the epithelial surface within twelve hours of mice starting to drink DSS-treated water, well before any inflammatory cells appear in the tissue.² This sequence matters because it establishes that in this model, inflammation is a consequence of barrier failure, not the other way around. The bacteria that suddenly gain access to the epithelium are what set off the immune system’s alarm.

It is worth noting that plain dextran, the parent sugar polymer without the sulfate groups, does not produce this effect. Both DSS and dextran can penetrate mucus, but only DSS alters its thickness and permeability.² The sulfate groups appear to be what makes DSS toxic to the mucus structure. This distinction has led researchers to propose that loss of the inner mucus layer could be an initiating event in human colitis as well, not just a side effect of ongoing inflammation.

The Innate Immune Response Fires First

Once bacteria contact epithelial cells, the innate immune system responds through pattern-recognition receptors. Two pathways stand out in DSS colitis: TLR4, which detects bacterial lipopolysaccharide on cell surfaces, and the NLRP3 inflammasome, which assembles inside cells in response to danger signals. DSS-treated colon tissue shows clearly increased NLRP3 activity compared to healthy controls.³ When these two pathways are working in balance, they help maintain barrier integrity and keep inflammation in check. When they become overactivated, they drive a self-reinforcing loop of epithelial damage, bacterial leakage, and escalating cytokine production.³

Histological examination of colon tissue during the acute phase, typically around day eight on a standard protocol, shows destruction of the tube-like crypts that house stem cells, loss of mucus-producing goblet cells, erosion of the epithelial surface, and heavy infiltration by neutrophils and eosinophils.⁴ This tissue damage gets worse with higher DSS concentrations, and it forms the basis of histological scoring systems that researchers use to quantify disease severity.

Adaptive Immunity and the Th17/Treg Tug-of-War

The adaptive immune system kicks in as inflammation persists. A consistent finding across studies is that DSS colitis drives a dramatic expansion of Th17 cells, a type of helper T cell that produces the inflammatory signaling molecules IL-17A, IL-17F, and IL-22. At the same time, regulatory T cells, or Tregs, which normally restrain immune responses, decline. This imbalance between pro-inflammatory Th17 cells and anti-inflammatory Tregs is a hallmark of the model.⁵ A separate population called Th22 cells, which produce IL-22 without IL-17A, also expands, suggesting the inflammatory response involves more cell types than initially appreciated.

The broader immune polarization of the host animal also matters. The two most commonly used mouse strains in colitis research, C57BL/6 and BALB/c, respond very differently to DSS. C57BL/6 mice lean toward a Th1-dominated immune profile, with high levels of the pro-inflammatory cytokines IFN-γ and TNF-α, and they develop severe colitis. BALB/c mice, by contrast, mount a Th2- and Treg-heavy response, with higher levels of IL-4 and IL-10, and are substantially more resistant to DSS.⁶ This difference reinforces the idea that the balance among T-cell subsets, not just the presence of inflammation, determines how badly the gut is damaged.

Treatments that tip the balance back toward regulation tend to be protective. IL-33, for instance, increases both regulatory B cells and Tregs in the lymph nodes while simultaneously decreasing Th17 responses, and it protects against chronic DSS colitis in mice.⁷

What Happens to the Microbiome

DSS does not just damage the host. It reshapes the microbial community living in the gut. Mice given DSS show reduced bacterial diversity and a shift in which groups dominate. The number of Bacteroidetes and Actinobacteria tends to drop, while Firmicutes and several classes of Proteobacteria increase.⁸ The same study found that DSS also altered microbial functional pathways, meaning the bacteria present were not just different in identity but in what they were doing metabolically.

As the disease becomes chronic through repeated DSS cycles, additional shifts emerge. Beneficial Lactobacillus species decline progressively, while Turicibacter species become more prevalent.⁹ The loss of microbial diversity is not merely a side effect; it feeds back into the disease process by reducing the production of beneficial metabolites that the gut lining depends on.

One of those metabolite classes is short-chain fatty acids, particularly butyrate, which is a primary energy source for colon cells and has anti-inflammatory properties. You might expect that supplementing butyrate would help. Surprisingly, at least one study found that neither butyrate alone nor a mixture of short-chain fatty acids improved weight loss, colon length, or histological inflammation in DSS-treated mice.¹⁰ However, a consortium of bacteria that produce short-chain fatty acids was able to increase mucus thickness and protect against colitis, likely because living bacteria do more than just supply one metabolite.¹¹ The distinction between supplementing a molecule and restoring a living microbial community is an important one that crops up repeatedly in microbiome research.

Systemic Effects Beyond the Gut

DSS colitis is often described as a model of intestinal inflammation, but its effects extend well beyond the colon. Metabolic profiling of DSS-treated mice reveals disturbances in lipid metabolism, energy metabolism, and the liver. Plasma amino acid levels rise, glucose drops in the liver, and oxidative stress markers change in the spleen.¹²

At higher DSS doses, the systemic picture becomes even more alarming. Mice develop inflammation in the liver and lungs, with elevated liver enzymes in the blood. The spleen shows increased cell death and reduced immune function, resembling what happens in sepsis. These findings suggest that severe gut barrier failure can produce a systemic inflammatory state driven by bacteria and bacterial products leaking from the gut into the bloodstream.¹³ In chronic DSS protocols, spleen weight increases progressively with repeated cycles of damage, along with rising counts of T cells and B cells in the spleen, suggesting the immune system is being chronically activated at a whole-body level.⁹

How Well the Model Mimics Human Ulcerative Colitis

DSS colitis is valued precisely because it shares many features with human ulcerative colitis. The inflammation is concentrated in the colon, damages the mucosal surface, destroys crypt architecture, and produces bloody diarrhea and weight loss. Gene expression profiling has shown that over 150 genes are similarly upregulated in DSS-treated mice and in human ulcerative colitis patients, spanning immune responses and tissue remodeling processes like blood vessel formation.¹⁴

The model is less suitable for studying Crohn’s disease, the other major form of inflammatory bowel disease, which can affect any part of the digestive tract and tends to involve deeper layers of the intestinal wall.¹⁵ Researchers studying Crohn’s-like pathology tend to use other models, such as those involving genetic modification or adoptive T-cell transfer, that better capture the transmural inflammation and granuloma formation characteristic of that disease.

Host Genetics Shape Susceptibility

Not all mice respond to DSS the same way, and the differences are instructive. A systematic comparison of inbred strains found dramatic variation in DSS susceptibility. C3H/HeJ mice and the autoimmune-prone NOD strain were highly susceptible, while NON mice, genetically close relatives of NOD, were quite resistant. The major histocompatibility complex, the set of immune genes most closely linked to autoimmunity in NOD mice, turned out not to be the deciding factor: NON mice carrying the same immune gene variant retained their resistance.¹⁶ This finding suggests that susceptibility to DSS colitis involves genes outside the classical autoimmune pathways.

Sex also plays a role. Male mice tend to develop more severe colonic lesions than females on the same DSS protocol, though cecal lesions do not show the same sex difference.¹⁶ The interaction between sex and strain background adds another layer of complexity to experimental design and interpretation.

From Inflammation to Cancer

Chronic inflammation in the colon is a known risk factor for colorectal cancer in humans, and the DSS model has been adapted to study this connection. The most common approach pairs DSS with azoxymethane, a chemical carcinogen, to create the AOM/DSS model of colitis-associated cancer. This combination produces tumors with histological and molecular features that closely resemble human colitis-associated colorectal cancer, and it is highly reproducible.¹⁷ The model has become a standard tool for testing whether anti-inflammatory or chemopreventive agents can interrupt the progression from chronic inflammation to dysplasia to frank cancer.

Tissue Repair and the Wnt Pathway

Recovery from DSS colitis depends on the gut’s ability to regenerate its epithelial lining, and the Wnt signaling pathway is central to that process. Wnt signals drive the proliferation of intestinal stem cells, which sit at the bottom of the crypts and continuously produce new epithelial cells. After DSS injury, experimental Wnt-activating compounds can expand the pool of stem and progenitor cells, boosting expression of cell-cycle genes across multiple epithelial cell types and accelerating re-epithelialization.¹⁸

Exosomes derived from human umbilical cord mesenchymal stem cells achieve something similar by activating Wnt signaling and upregulating the intestinal stem cell marker Lgr5, promoting both stem cell activity and epithelial regeneration.¹⁹ These findings are generating interest in Wnt-based regenerative therapies for IBD patients whose disease does not respond well to conventional anti-inflammatory drugs.

Testing Drugs in the DSS Model

One of the model’s primary uses is evaluating potential treatments. The results are sometimes surprising. In a head-to-head comparison, mesalazine and olsalazine, two aminosalicylates that are first-line treatments in human ulcerative colitis, were only weakly active in acute DSS colitis and in some cases made it worse. Cyclosporine reduced colitis in a dose-dependent manner, and combining it with olsalazine produced a stronger effect than either drug alone.²⁰ Anti-TNF-α therapy, which targets a key inflammatory cytokine, reduced immune cell infiltration and restored both mucosal integrity and fluid absorption in chronic DSS colitis, even while DSS exposure continued.²¹

The fact that some drugs effective in human IBD perform poorly in DSS colitis, while others work well, underscores that this is a model, not a replica. The chemical nature of DSS-driven barrier damage is fundamentally different from the immune-mediated barrier damage seen in most human ulcerative colitis, and this discrepancy can lead drugs to behave differently in the two settings.

Practical Pitfalls and Reproducibility Challenges

For all its usefulness, DSS colitis is notoriously sensitive to experimental conditions. The gut microbiota varies between animal facilities and even between cages in the same facility, and these differences can shift disease severity and immune phenotypes substantially.²² The molecular weight of the DSS itself matters, as do batch-to-batch differences from the manufacturer. Different lots of nominally identical DSS can produce noticeably different levels of colitis, which means labs often need to empirically test each new batch before running an actual experiment.²³

Diet is another underappreciated variable. Defined diets, whether high-fat or low-fat, can worsen DSS colitis compared to standard chow. Adding the fermentable fiber inulin, which is often considered gut-friendly, actually exacerbated colitis severity and worsened clinical symptoms like weight loss and bleeding on both high- and low-fat defined diets.²⁴ The insoluble fiber cellulose did not have the same effect. This result is a good reminder that “fiber is good for the gut” is too simple a statement, especially when the gut barrier is already compromised.

Chronic DSS protocols add another layer of complexity. Non-invasive measurements like stool consistency and body weight often fail to capture ongoing inflammation during remission phases between DSS cycles. Researchers who rely only on these external markers can underestimate disease severity in chronic models, where internal measurements such as colon weight, inflamed tissue area, and immune cell counts continue to worsen even when the animal looks clinically better.⁹

The Enteric Nervous System and Gut-Brain Communication

An area of growing interest in DSS colitis research is the role of the enteric nervous system, the network of neurons embedded in the gut wall. Experimental colitis has shown that neurotransmitters and cytokines mediate a two-way conversation between nerve cells and immune cells in the intestine. This crosstalk can go either direction: some nerve-derived signals dampen inflammation while others amplify it.²⁵ The vagus nerve, which connects the brain to the gut, can trigger a systemic anti-inflammatory response when activated during intestinal inflammation. Vagus nerve stimulation enhances enteric nervous system activity, reduces inflammatory cytokine production by immune cells, and modulates gut motility. This “inflammatory reflex” has inspired clinical interest in vagus nerve stimulation as a potential therapy for IBD, though translating results from colitis models into effective human treatments remains a work in progress.²⁵

Epigenetic Regulation and microRNAs

Beyond the cell types and signaling molecules already discussed, DSS colitis also involves changes at the level of gene regulation. Small non-coding RNA molecules called microRNAs act as fine-tuners of gene expression, and recent work has linked specific microRNAs to the regulation of inflammatory responses, barrier integrity, and the development of fibrosis in both experimental and clinical IBD.²⁶ Because microRNAs can simultaneously regulate many target genes, they represent potential therapeutic targets that could modulate entire inflammatory programs rather than blocking a single cytokine. This field is still in its early stages, but it adds a layer of regulation that helps explain why genetically identical mice in different environments can develop such different disease courses when exposed to the same DSS protocol.